Literature DB >> 17318396

Galectin-3 in apoptosis, a novel therapeutic target.

Pratima Nangia-Makker1, Susumu Nakahara, Victor Hogan, Avraham Raz.   

Abstract

During the past decade, extensive progress has been made toward understanding the molecular basis for the regulation of apoptosis. In mammalian cells undergoing apoptosis, two distinct mechanisms or pathways are operated and are triggered by cell death stimuli from intra- or extra-cellular environments, namely the intrinsic or extrinsic pathways, resulting in mitochondrial membrane depolarization. Several lines of evidence from our laboratories and others have indicated that galectin-3 plays an important role in these pathways by binding to various ligands. Here the authors provide a brief discussion on the role of endogenous or extra-cellular galectin-3 in the regulation of apoptosis and how it could be used as a therapeutic target using natural plant products as its functional inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318396      PMCID: PMC3616377          DOI: 10.1007/s10863-006-9063-9

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  67 in total

Review 1.  The central executioners of apoptosis: caspases or mitochondria?

Authors:  D Green; G Kroemer
Journal:  Trends Cell Biol       Date:  1998-07       Impact factor: 20.808

2.  Regulation of cellular adhesion to extracellular matrix proteins by galectin-3.

Authors:  J Ochieng; M L Leite-Browning; P Warfield
Journal:  Biochem Biophys Res Commun       Date:  1998-05-29       Impact factor: 3.575

Review 3.  Death receptors: signaling and modulation.

Authors:  A Ashkenazi; V M Dixit
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

4.  Two CD95 (APO-1/Fas) signaling pathways.

Authors:  C Scaffidi; S Fulda; A Srinivasan; C Friesen; F Li; K J Tomaselli; K M Debatin; P H Krammer; M E Peter
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

5.  Role of the carboxyl-terminal lectin domain in self-association of galectin-3.

Authors:  R Y Yang; P N Hill; D K Hsu; F T Liu
Journal:  Biochemistry       Date:  1998-03-24       Impact factor: 3.162

6.  Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.

Authors:  H Li; H Zhu; C J Xu; J Yuan
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

7.  Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.

Authors:  X Luo; I Budihardjo; H Zou; C Slaughter; X Wang
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

Review 8.  TRAIL: a molecule with multiple receptors and control mechanisms.

Authors:  T S Griffith; D H Lynch
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

Review 9.  Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis.

Authors:  M E Peter; P H Krammer
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

Review 10.  Apoptosis signaling by death receptors.

Authors:  K Schulze-Osthoff; D Ferrari; M Los; S Wesselborg; M E Peter
Journal:  Eur J Biochem       Date:  1998-06-15
View more
  45 in total

1.  Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.

Authors:  Mio Yamamoto-Sugitani; Junya Kuroda; Eishi Ashihara; Hisao Nagoshi; Tsutomu Kobayashi; Yosuke Matsumoto; Nana Sasaki; Yuji Shimura; Miki Kiyota; Ryuko Nakayama; Kenichi Akaji; Tomohiko Taki; Nobuhiko Uoshima; Yutaka Kobayashi; Shigeo Horiike; Taira Maekawa; Masafumi Taniwaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

2.  Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin.

Authors:  Tsutomu Kobayashi; Tatsuo Shimura; Toshiki Yajima; Norio Kubo; Kenichiro Araki; Soichi Tsutsumi; Hideki Suzuki; Hiroyuki Kuwano; Avraham Raz
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

3.  Quinoline-Pyrazole Scaffold as a Novel Ligand of Galectin-3 and Suppressor of TREM2 Signaling.

Authors:  Moustafa Gabr; Ashfaq Ur Rehman; Hai-Feng Chen
Journal:  ACS Med Chem Lett       Date:  2020-08-11       Impact factor: 4.345

Review 4.  Why anti-Bcl-2 clinical trials fail: a solution.

Authors:  Y Harazono; K Nakajima; A Raz
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

5.  Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells.

Authors:  Praveenkumar Shetty; Anil Bargale; Basavraj R Patil; Rajashekar Mohan; U S Dinesh; Jamboor K Vishwanatha; Pramod B Gai; Vidya S Patil; T S Amsavardani
Journal:  Mol Cell Biochem       Date:  2015-10-05       Impact factor: 3.396

6.  Differential cellular localization of galectin-1 and galectin-3 in the regressing corpus luteum of mice and their possible contribution to luteal cell elimination.

Authors:  Junko Nio-Kobayashi; Toshihiko Iwanaga
Journal:  J Histochem Cytochem       Date:  2010-04-26       Impact factor: 2.479

Review 7.  Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function.

Authors:  Ya Zhuo; Susan L Bellis
Journal:  J Biol Chem       Date:  2010-12-20       Impact factor: 5.157

8.  Design and synthesis of glycoprotein-based multivalent glyco-ligands for influenza hemagglutinin and human galectin-3.

Authors:  Helen Wang; Wei Huang; Jared Orwenyo; Aditi Banerjee; Gerardo R Vasta; Lai-Xi Wang
Journal:  Bioorg Med Chem       Date:  2013-01-23       Impact factor: 3.641

9.  Immunohistochemical localization of six galectin subtypes in the mouse digestive tract.

Authors:  Junko Nio-Kobayashi; Hiromi Takahashi-Iwanaga; Toshihiko Iwanaga
Journal:  J Histochem Cytochem       Date:  2008-09-15       Impact factor: 2.479

10.  Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice.

Authors:  Miranda S Oakley; Victoria Majam; Babita Mahajan; Noel Gerald; Vivek Anantharaman; Jerrold M Ward; Lawrence J Faucette; Thomas F McCutchan; Hong Zheng; Masaki Terabe; Jay A Berzofsky; L Aravind; Sanjai Kumar
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.